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ABSTRACT
INTRODUCTION: The role of the thymus gland and the effects of thymic peptides on the coagulation status 
are relatively insufficiently studied. Recent data indicate controversial and not persuasive results due to in-
vestigation of single hemostasis parameters and application of various pathological models.
AIM: The present study aimed to elucidate the influence of thymus peptides thymulin, thymosin alpha 1 
and thymosin beta 4 applied s.c. on intact rats, on key triggering factors of blood coagulation via the extrin-
sic pathway: plasma concentration of tissue factor (TF); concentration and activity of free TFPI; and the ac-
tivity of plasma clotting factor VII, as well as on prothrombin time (PT) – an integral clinical parameter of 
the intrinsic pathway.
MATERIALS AND METHODS: The study was performed on 52 male Wistar strain rats, weighing 200-220 g 
and  bred under standard conditions at dark/light cycle 12/12 h. The rats were divided into four equal groups 
(n=13) and injected s.c. once daily in the time interval 08.00-09.00 h in the course of three consecutive days 
as follows: 1st group (controls) - with saline (the solvent of the peptides); 2nd group – with thymulin (Sigma 
Aldrich, 0.4 mg/kg b.m.); 3rd group – with thymosin alpha 1 (Sigma Aldrich, 0.3 mg/kg b.m.); and the 4th 
group – with thymosin beta 4 (Sigma Aldrich, 0.3 mg/kg b.m.).
RESULTS: Results indicate that thymulin and thymosin alpha 1 expressively decrease TF and increase TFPI 
concentrations. All three thymic peptides reduce FVIIa activity, increase TFPI activity, and significantly 
elongate PT.
CONCLUSIONS: Thymus peptides thymulin, thymosin alpha 1 and thymosin beta 4 significantly suppress 
blood coagulation through the extrinsic pathway and generate a distinct tendency for hypocoagulability.
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INTRODUCTION 
The blood coagulation system is based on cas-
cade activation of a series of enzyme reactions where 
proenzymes and profactors are activated by serine 
proteases through limited proteolysis. Activation of 
hemocoagulation may be performed by two basic 
pathways: intrinsic and extrinsic (1). The tissue fac-
tor (TF) is the principle activator of the coagulation 
cascade via the extrinsic pathway (2). Endothelial 
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Though the numerous clinical and experimen-
tal studies are focused on the links between endo-
crine disorders and deviation of the blood coagula-
tion status (17), the role of the thymus gland and its 
effects on hemostasis are relatively insufficiently de-
fined. The existing literature data are scarce and pre-
dominantly based on pathological models with thy-
mectomy or after application of higher doses of thy-
mic extracts (18). Moreover, a lot of studies are fo-
cused on measurement of single hemostasis param-
eters leading to incomplete and controversial results 
(19). 
The present study aims to investigate the in-
fluence of the thymus peptides thymulin, thymosin 
alpha 1 and thymosin beta 4 applied on intact (not 
thymectomized) rats, on plasma concentration of 
TF, free TFPI; and on the activity of plasma clotting 
factor VII and free TFPI, as well as on prothrombin 
time – an integral clinical parameter of the intrinsic 
pathway.
MATERIALS AND METHODS
The study was performed on 52 male Wistar 
strain rats. Rats weighing 200-220 g were bred under 
standard conditions at dark/light cycle 12/12 h, with 
free access to standard briquette chew and water. The 
animals were treated according to the requirements 
of the European Convention for the Protection of Ex-
perimental Animals (Protection of animals used for 
experimental purposes, Council Directive 86/609/
EEC of November 1986) and Directive 2010/63/EU 
of the European Parliament and of the Council of 
Europe, September 2010. The rats were divided into 
four equal groups (13 rats in a group) – one control 
and three experimental and injected subcutaneously 
once daily in the time interval 08.00-09.00 h in the 
course of three consecutive days as follows: 1st group 
- with saline (the solvent of the peptides); 2nd group 
– with thymulin (Sigma Aldrich, 0.4 mg/kg b.m.); 
3rd group – with thymosin alpha 1 (Sigma Aldrich, 
0.3 mg/kg b.m.); and the 4th group – with thymo-
sin beta 4 (Sigma Aldrich, 0.3 mg/kg b.m.). The pep-
tides used were in the form of a dry substance and 
were dissolved ex tempore. The doses used were de-
fined on the basis of literature data, and through a 
preliminary analyses for determination of logarith-
mic dose–effect dependence. Experiments were car-
ried out during the period of spring equinox. The ob-
barrier injury allows TF binding to FVII/FVIIa and 
formation of the so-called tenase complex (TF/FVI-
Ia). TF/FVIIa, phospholipid membranes and calcium 
ions catalyze conversion of plasma clotting factors 
IX into IXa, and X into Xa (3). The last phenomenon 
is considered a pivotal step of the blood coagulation 
process initiating the common end pathway leading 
to formation of thrombin and the consecutive forma-
tion of fibrin mesh (4). The regulatory subunit of the 
tenase complex - TF (tissue thromboplastin, CD142), 
is a transmembrane glycoprotein belonging to the su-
perfamily of class II cytokine receptors. It is abun-
dant in vascular smooth muscle cells, pericytes and 
adventitial fibroblasts with excessively high levels in 
brain, lungs, placenta, uterus and testis (5). The cata-
lytic subunit, FVII, is a vitamin K-dependent plasma 
protein from the family of trypsin-like serine proteas-
es, which is in an active form of about 1% (6). Knock-
out of TF and FVII genes is lethal and indicates the 
essential role of those elements in hemostasis (7). Tis-
sue factor pathway inhibitor (TFPI) is the basic phys-
iological anticoagulation mechanism of TF-initiated 
coagulation cascade (8) highly involved in the initia-
tion of blood coagulation via the extrinsic pathway 
(9). Its molecule predominantly synthesized in vas-
cular endothelium consists of three inhibitor Kunitz-
type domains (K1, K2 and K3). K1 binds the tenase 
complex (TF/FVIIa), while K2 binds FXa. The com-
plex formed TFPI/TF/FVIIa/FXa is inactive and de-
termines the suppressive hemocoagulation effect of 
TFPI (10). TFPI inhibits prothrombin activator for-
mation responsible for conversion of prothrombin to 
thrombin by inactivation of FXa and FVa (11). De-
viations of concentrations and activities of the com-
ponents of the complex TF/FVIIa, as well as devia-
tions of concentrations and activities of its inhibitor 
- TFPI, are reported in various clinical disorders (12). 
Prothrombin time (PT) is a basic common integral 
parameter of hemocoagulation (13). It is widely ap-
plied in clinical practice for estimation of blood co-
agulation factors via the extrinsic and the common 
pathways of fibrin formation (14), as well as for a 
screening test for deficiencies of plasma clotting fac-
tors involved in those pathways (II, V, VII, X and fi-
brinogen) (15). Moreover, in clinical practice, PT cal-
culated as INR is used for estimation of the efficacy 
of classic oral anticoagulation therapy (16).
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servation period duration was 72 hours. The neces-
sary blood volume from a rat (4.5 ml) was obtained 
in a plastic single usage syringe by a cardiac punc-
ture under urethane narcosis (blood/anticoagulant 
ratio 9:10). Sodium citrate (0.11 mol/l) was used as 
an anticoagulant. Centrifugion duration was 10 min-
utes at 3000 rev/min. The supernatant was separated 
and stored at 4 ºС in hemostatic test tubes. The coag-
ulation parameter PT was determined not later than 
2 hours by reactives of Diagnostica Stago, France on 
coagulometer Coag-Mate XM. The rest of the plasma 
was frozen and stored at -60 ºС for the measurement 
of the other parameters, which were evaluated no lat-
er than 10 days after this.
TF was determined by ELISA method using a 
kit by American Diagnostica inc., USA. Free TFPI ac-
tivity and free TFPI concentration were estimated by 
conventional ELISA method with kits by Diagnosti-
ca Stago, France. Factor VII activity was determined 
on coagulometer Coag-Mate XM by conventional ki-
netic coagulometric methods applied elsewhere us-
ing a test by Dade Behring, USA. At the end of the 
experiments the animals were autopsied and macro-
scopically inspected for hemorrhages. Slices from the 
internal organs (kidney, liver, stomach and spleen) 
were prepared and stained by hematoxylin-eozyne 
and by Weigert for fibrin for the exclusion of micro-
hemorrhages and/or intravascular coagulation.
All data were analyzed by variation analysis, 
by Student-Fisher’s t-test, using GraphPad Prism 
5 software product. The results are presented as 
MEAN±SEM. Values of p less than 0.05 were consid-
ered significant.
RESULTS 
Figure 1 illustrates that thymic peptides thy-
mulin and thymosin alpha 1 significantly re-
duced (р<0.0001) TF plasma concentration from 
199.7±13.60 ng/ml (control group) respectively to 
95.21±14.46 ng/ml and 113.5±9.50 ng/ml. Thymosin 
beta 4 application did not lead to significant changes 
of this parameter (184.9±32.10 ng/ml).
In Fig. 2 the effects of thymus peptides on free 
TFPI plasma concentration are presented. Thymu-
lin and thymosin alpha 1 generated significant el-
evation of free TFPI plasma concentration respec-
tively  to 23.70±3.95 ng/ml (р<0.001) and 16.92±1.23 
ng/ml (р<0.0001) versus the control group values 
(10.54±0.65 ng/ml), while the effect of thymosin beta 
4 was not significant (9.902±1.37 ng/ml). 
The activity of free TFPI expressed in percent-
age is illustrated in Fig. 3. All the three peptides in-
creased free TFPI activity as follows: 130.3±9.49; 
p<0.001 (thymulin), 151.6±19.24; p<0.001 (thymosin 
alpha 1) and 139.9±20.85; p<0.01 (thymosin beta 4), 
compared to the control group (91.88±7.94).
Factor VII activity (Fig. 4) was significant-
ly reduced (р<0.0001) by the three peptides from 
110.4±6.96 (controls) to 55.09±7.04, 67.91±7.63 and 
50.06±7.01, respectively for thymulin, thymosin al-
pha 1 and thymosin beta 4.
Figure 1. Еffects of thymulin (0.4 mg/kg b.m.), thymosin 
alpha 1 (0.3 mg/kg b.m.) and thymosin beta 4 (0.3 mg/kg 
b.m.) on tissue factor (TF) plasma concentration. Data 
are presented as MEAN±SEM, n=13
*** - p<0. 0001, C-control; Т-thymulin; Тα1-thymosin al-
pha 1; Тβ4-thymosin beta 4; ns-nonsignificant.
Figure 2. Еffects of thymulin (0.4 mg/kg b.m.), thymosin 
alpha 1 (0.3 mg/kg b.m.) and thymosin beta 4 (0.3 mg/kg 
b.m.) on tissue factor pathway inhibitor (TFPI) plasma 
concentration. Data are presented as MEAN±SEM, n=13
***- p<0.0001, **- p< 0.001, C-control; Т-thymulin; 
Тα1-thymosin alpha 1; Тβ4-thymosin beta 4; 
ns-nonsignificant.
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Figure 5 demonstrates that the peptides applied 
elongate PT to 21.45±2.67 sec., p<0.001 (thymulin), 
26.96±2.19 sec., p<0.0001  (thymosin alpha 1) and 
20.99±1.50 sec., p<0.0001 (thymosin beta 4), com-
pared to the control group (11.66±0.78 sec.).
Macroscopic inspections and histological 
studies did not indicate any signs of thrombosis or 
hemorrhage.
DISCUSSION 
Low TF levels in clinical practice, as well as ap-
plication of TF antibodies in animal experiments are 
associated with massive lung, brain, heart and testis 
hemorrhages (5). As far as inborn factor VII deficien-
cy is concerned, clinical data are rather controversial 
indicating both tendency of hemorrhage, as well as 
thrombotic incidents (6). Human recombinant fac-
tor VII is applied with a success in the therapy of se-
vere hemorrhages.
Thymus peptides thymulin and thymosin al-
pha 1 reduced significantly (p<0.0001) TF plasma 
concentration in this study (Fig. 1). Tissue factor 
pathway inhibitor (TFPI) is postulated to suppress 
hemocoagulation by blockade of both the activity of 
the complex TF/FVIIa (20), and the prothrombinase 
complex (10). The clinical manifestations of elevat-
ed TFPI most commonly comprise frequent hemor-
rhages, menorrhagiae and life-threatening bleeding 
after trauma or surgical intervention (6,7). Block-
ing of TFPI activity recovers the process of throm-
bin formation via the extrinsic pathway and normal-
izes the hemostatic process. Pharmacological agents 
suppressing TFPI activity are reported to be applied 
in hemophilia treatment (21). In this study thymulin 
and thymosin alpha 1 elevated free TFPI concentra-
tion, while thymosin beta 4 did not impact signifi-
cantly this parameter (Fig. 2). TFPI activity was con-
siderably increased by the three thymic peptides (Fig. 
3). Having in mind the mechanism(s) of the effect of 
TFPI, one could easily explain the shifts of the ac-
tivity of plasma clotting factor VIIa (Fig. 4), which 
is in harmony with TFPI significantly decreased 
(p<0.0001) by the three peptides. These data allow 
the presumption, though speculatively, that a low-
er rate of formation of the tenase complex TF/FVIIa 
Figure 3. Еffects of thymulin (0.4 mg/kg b.m.), thymosin 
alpha 1 (0.3 mg/kg b.m.) and thymosin beta 4 (0.3 mg/kg 
b.m.) on tissue factor pathway inhibitor (TFPI) activity. 
Data are presented as MEAN±SEM, n=13
* - p<0.01, ** - p<0.001, C-control; Т-thymulin; 
Тα1-thymosin alpha 1; Тβ4-thymosin beta 4; 
ns-nonsignificant.
Figure 4. Еffects of thymulin (0.4 mg/kg b.m.), thymosin 
alpha 1 (0.3 mg/kg b.m.) and thymosin beta 4 (0.3 mg/kg 
b.m.) on plasma clotting factor VII activity. Data are pre-
sented as MEAN±SEM, n=13
***- p<0.0001, C-control; Т-thymulin; Тα1-thymosin al-
pha 1; Тβ4-thymosin beta 4; ns-nonsignificant.
Figure 5. Еffects of thymulin (0.4 mg/kg b.m.), thymosin 
alpha 1 (0.3 mg/kg b.m.) and thymosin beta 4 (0.3 mg/kg 
b.m.) on prothrombin time (PT). Data are presented as 
MEAN±SEM, n=13
**- p<0.001, ***- p<0.0001, C-control; Т-thymulin; 
Тα1-thymosin alpha 1; Тβ4-thymosin beta 4; 
ns-nonsignificant.
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is involved in the initial phase of blood coagulation 
via the extrinsic pathway. Upper result analysis es-
tablishes that thymus peptides thymulin, thymosin 
alpha 1 and thymosin beta 4 undoubtedly generate a 
noticeable tendency of hypocoagulability. PT is a pa-
rameter highly informative about the integrity of the 
coagulation process via the extrinsic and common 
pathway cascades (5). Data in Figure 5 indicating sig-
nificant lengthening of PT by thymulin (p<0.001), 
thymosin alpha 1 and thymosin beta 4 (p<0.0001) 
are in good harmony with the changes of the other 
parameters studied, supporting the tendency of re-
duced coagulability. 
CONCLUSION
The results of this study illustrate that thymic 
peptides thymulin, thymosin alpha 1 and thymosin 
beta 4 exert substantial effect on the processes in-
volved in the initiating mechanism of blood coagu-
lation via the extrinsic pathway. Thymulin and thy-
mosin alpha 1 significantly reduce TF concentration, 
at the same time elevate the plasma concentration of 
its principal inhibitor – TFPI, while thymosin beta 4 
does not influence these parameters. The three thy-
mic peptides increase TFPI activity and decrease 
FVIIa activity and elongate PT. These data evidence 
that thymulin, thymosin alpha 1 and thymosin beta 
4 applied on intact rats inhibit the trigger mechanism 
of hemocoagulation via the extrinsic pathway creat-
ing a distinct tendency of hypocoagulability. 
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